The presence of distant metastases is a common finding on diagnosis of pancreatic cancer; however, the mechanisms underlying the dissemination of this tumor type remain poorly understood. Loss of the p53 tumor suppressor protein has been associated with tumor progression and metastasis in several tumor types including pancreatic ductal adenocarcinoma. Here, we describe the generation of a progressive and metastatic pancreatic cancer mouse model after the somatic and sporadic delivery of avian retroviruses encoding the mouse polyoma virus middle T antigen to elastase-tv-a transgenic mice with a pancreas-specific deletion of the Trp53 tumor suppressor locus. In this model, the tumors metastasize most frequently to the liver, consistent with h...
Pancreatic cancer is one of the deadliest human malignancies, and its prognosis has not improved ove...
Pancreatic cancer is one of the deadliest human malignancies, and its prognosis has not improved ove...
Background & Aims One treatment strategy for pancreatic ductal adenocarcinoma is to modify, ...
The presence of distant metastases is a common finding on diagnosis of pancreatic cancer; however, t...
The presence of distant metastases is a common finding on diagnosis of pancreatic cancer; however, t...
SummaryTo define the genetic requirements for pancreatic ductal adenocarcinoma (PDA), we have target...
AbstractIn human studies and mouse models, the contributions of p53 and p16Ink4a/p19Arf loss are wel...
In human studies and mouse models, the contributions of p53 and p16Ink4a/p19Arf loss are well establ...
TP53 mutation occurs in 50–75% of human pancreatic ductal adenocarcinomas (PDAC) following an initia...
Pancreatic ductal adenocarcinoma (PDA) is a deadly disease with few treatment options. There is an u...
Pancreatic cancer is characterized by nearly universal activating mutations in KRAS. Among other som...
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. HCC patients fr...
BACKGROUND: Pancreatic cancer is a deadly disease characterised by high incidence of TP53 mutations....
A human pancreatic cancer progression model from intraepithelial neoplasia to ductal adenocarcinoma ...
AbstractIn human studies and mouse models, the contributions of p53 and p16Ink4a/p19Arf loss are wel...
Pancreatic cancer is one of the deadliest human malignancies, and its prognosis has not improved ove...
Pancreatic cancer is one of the deadliest human malignancies, and its prognosis has not improved ove...
Background & Aims One treatment strategy for pancreatic ductal adenocarcinoma is to modify, ...
The presence of distant metastases is a common finding on diagnosis of pancreatic cancer; however, t...
The presence of distant metastases is a common finding on diagnosis of pancreatic cancer; however, t...
SummaryTo define the genetic requirements for pancreatic ductal adenocarcinoma (PDA), we have target...
AbstractIn human studies and mouse models, the contributions of p53 and p16Ink4a/p19Arf loss are wel...
In human studies and mouse models, the contributions of p53 and p16Ink4a/p19Arf loss are well establ...
TP53 mutation occurs in 50–75% of human pancreatic ductal adenocarcinomas (PDAC) following an initia...
Pancreatic ductal adenocarcinoma (PDA) is a deadly disease with few treatment options. There is an u...
Pancreatic cancer is characterized by nearly universal activating mutations in KRAS. Among other som...
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. HCC patients fr...
BACKGROUND: Pancreatic cancer is a deadly disease characterised by high incidence of TP53 mutations....
A human pancreatic cancer progression model from intraepithelial neoplasia to ductal adenocarcinoma ...
AbstractIn human studies and mouse models, the contributions of p53 and p16Ink4a/p19Arf loss are wel...
Pancreatic cancer is one of the deadliest human malignancies, and its prognosis has not improved ove...
Pancreatic cancer is one of the deadliest human malignancies, and its prognosis has not improved ove...
Background & Aims One treatment strategy for pancreatic ductal adenocarcinoma is to modify, ...